SF3B1 inhibition disrupts malignancy and prolongs survival in glioblastoma patients through BCL2L1 splicing and mTOR/ß-catenin pathways imbalances.

Antonio C Fuentes-FayosJesús M Pérez-GómezMiguel E G-GarcíaJuan M Jiménez-VacasCristóbal Blanco-AcevedoRafael Sánchez-SánchezJuan SoliveraJoshua J BreunigManuel D GaheteJusto P CastañoRaul Miguel Luque

Published in: Journal of experimental & clinical cancer research : CR (2022)

Together, we highlight SF3B1 as a potential diagnostic and prognostic biomarker and an efficient pharmacological target in glioblastoma, offering a clinically relevant opportunity worth to be explored in humans.

Keyphrases

end stage renal disease
ejection fraction
cell proliferation
newly diagnosed
chronic kidney disease
patient reported outcomes
signaling pathway